{"id":4096,"date":"2019-05-21T11:05:14","date_gmt":"2019-05-21T09:05:14","guid":{"rendered":"https:\/\/thoraxzentrum-ruhrgebiet.de\/calismalar\/"},"modified":"2026-10-21T14:06:39","modified_gmt":"2026-10-21T12:06:39","slug":"calismalar","status":"publish","type":"page","link":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/calismalar\/","title":{"rendered":"\u00c7al\u0131\u015fmalar"},"content":{"rendered":"

\u0130la\u00e7, t\u0131bbi cihaz, giri\u015fimsel olmayan \u00e7al\u0131\u015fmalar, klinik kay\u0131tlar ve kendi inisiyatifimizle ba\u015flatt\u0131\u011f\u0131m\u0131z \u00e7al\u0131\u015fmalar arac\u0131l\u0131\u011f\u0131yla toraks cerrahisi, pn\u00f6moloji ve onkoloji alanlar\u0131ndaki ara\u015ft\u0131rmalar\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde ileriye ta\u015f\u0131yoruz. Amac\u0131m\u0131z, mevcut bilgi d\u00fczeyini geni\u015fletmek ve kontroll\u00fc ko\u015fullar alt\u0131nda yeni tedavi y\u00f6ntemlerini denemek ve de\u011ferlendirmektir.<\/p>\n

\u00c7al\u0131\u015fma t\u00fcrleri<\/h5>\n

Temel olarak retrospektif ve prospektif \u00e7al\u0131\u015fmalar aras\u0131nda ayr\u0131m yap\u0131l\u0131r. Retrospektif incelemeler, \u00f6rne\u011fin mevcut hasta dosyalar\u0131ndan verilerin \u00e7\u0131kar\u0131lmas\u0131 veya toplanm\u0131\u015f t\u00fcm\u00f6r \u00f6rnekleri \u00fczerinde \u00f6l\u00e7\u00fcm yap\u0131lmas\u0131 gibi, halihaz\u0131rda mevcut verilerin de\u011ferlendirilmesidir.<\/p>\n

Prospektif incelemeler ise belirli verilerin gelecekte toplanmas\u0131n\u0131 planlar ve inceleme s\u00fcresi tamamland\u0131ktan sonra bunlar\u0131 de\u011ferlendirir. \u00d6rne\u011fin, gelecek y\u0131l\u0131n t\u00fcm t\u00fcm\u00f6r \u00f6rnekleri belirli bir \u00f6zelli\u011fin varl\u0131\u011f\u0131 a\u00e7\u0131s\u0131ndan incelenir ve ard\u0131ndan bu hastalar\u0131n sonraki seyri takip edilir.<\/p>\n

Prospektif \u00e7al\u0131\u015fmalar\u0131n \u00f6zel bir t\u00fcr\u00fc, \u00f6rne\u011fin bir t\u0131bbi giri\u015fimin (\u00f6rn. yeni bir ilac\u0131n) etkinli\u011finin belirlenmesinin ama\u00e7land\u0131\u011f\u0131, s\u00f6zde m\u00fcdahale \u00e7al\u0131\u015fmalar\u0131d\u0131r. Bu \u00e7al\u0131\u015fmalarda hastalar\u0131n yaln\u0131zca bir k\u0131sm\u0131 yeni ilac\u0131 al\u0131rken, di\u011ferleri standart tedaviyi al\u0131r. T\u00fcm hastalar\u0131n hastal\u0131k seyrinin izlenmesiyle, yeni ilac\u0131n mevcut standarda g\u00f6re daha iyi (veya daha k\u00f6t\u00fc) olup olmad\u0131\u011f\u0131 anla\u015f\u0131labilir. \u0130yi ve adil bir kar\u015f\u0131la\u015ft\u0131rma i\u00e7in, di\u011fer etkileyen fakt\u00f6rlerin (\u00f6rn. ya\u015f, hastal\u0131k evresi, motivasyon) her iki grupta da dengeli bi\u00e7imde da\u011f\u0131ld\u0131\u011f\u0131ndan emin olunmal\u0131d\u0131r. Bu, \u201crandomizasyon\u201d olarak adland\u0131r\u0131lan y\u00f6ntemle, yani her bir hastan\u0131n iki gruptan birine rastgele atanmas\u0131yla en iyi \u015fekilde sa\u011flan\u0131r.<\/p>\n

Hasta kimli\u011fini (s\u00f6zde \u201cki\u015fisel veriler\u201d) i\u00e7eren t\u00fcm \u00e7al\u0131\u015fmalar, hastan\u0131n \u00f6nceden bilgilendirilmi\u015f onay\u0131n\u0131 gerektirir; hasta bu onay\u0131 diledi\u011fi zaman geri \u00e7ekebilir. Bu durum, tedavi t\u00fcr\u00fcn\u00fcn \u00e7al\u0131\u015fma taraf\u0131ndan belirlendi\u011fi m\u00fcdahale \u00e7al\u0131\u015fmalar\u0131nda \u00f6zellikle ge\u00e7erlidir. Bu, zaman zaman k\u00f6t\u00fcye kullan\u0131m \u015f\u00fcphesi nedeniyle hastalarda veya \u00fc\u00e7\u00fcnc\u00fc ki\u015filerde (\u201cdenek\u201d) g\u00fcvensizli\u011fe yol a\u00e7abilmektedir. Yeterli bilgilendirme ve dolay\u0131s\u0131yla \u015feffafl\u0131k bunun \u00f6n\u00fcne ge\u00e7ebilir. Bu ba\u011flamda \u00f6nemli olan, bu \u00e7al\u0131\u015fmalar\u0131n yaln\u0131zca kapsaml\u0131 bi\u00e7imde bilgilendirilmi\u015f hastan\u0131n onay\u0131yla yap\u0131labilmesi ve ayr\u0131ca ba\u011f\u0131ms\u0131z bir etik kurul taraf\u0131ndan incelenip onaylanmas\u0131n\u0131n gerekmesidir. Veriler, \u00e7al\u0131\u015fma merkezine yaln\u0131zca anonimle\u015ftirilmi\u015f bi\u00e7imde iletilir. Rutin olarak bir hasta sigortas\u0131 yap\u0131l\u0131r.<\/p>\n

Standart tedavi alan hastalar\u0131n daha k\u00f6t\u00fc tedavi edilece\u011fi endi\u015fesine kar\u015f\u0131, kar\u015f\u0131la\u015ft\u0131rmalar\u0131n etik a\u00e7\u0131dan ancak hangi tedavinin daha iyi oldu\u011funun bilinmedi\u011fi durumlarda savunulabilir oldu\u011fu belirtilmelidir. Ayr\u0131ca, yeni tedavinin eskiye \u00fcst\u00fcn oldu\u011fu zaten bilinseydi, bir \u00e7al\u0131\u015fma y\u00fcr\u00fctmek i\u00e7in bu kadar \u00e7aba da g\u00f6sterilmezdi.<\/p>\n<\/div><\/section>\n

\n

Akci\u011fer karsinomu<\/h4>\n
    \n
  • CRISP g\u00f6zlemsel \u00e7al\u0131\u015fmas\u0131
    \nK\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer karsinomu olan hastalarda molek\u00fcler biyobelirte\u00e7lerin, tedavinin ve tedavi sonucunun incelenmesine y\u00f6nelik g\u00f6zlem<\/li>\n
  • FINN g\u00f6zlemsel \u00e7al\u0131\u015fmas\u0131
    \nK\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer karsinomunda 2 kemoterapi d\u00f6ng\u00fcs\u00fc ile Nivolumab + \u0130pilimumab tedavisine y\u00f6nelik g\u00f6zlemsel \u00e7al\u0131\u015fma<\/li>\n<\/ul>\n

    Plevral mezotelyoma<\/strong><\/h4>\n
      \n
    • Plevra t\u00fcm\u00f6r\u00fc kayd\u0131
      \nMalign plevral mezotelyomada yerle\u015fik, ancak \u00f6zellikle de yeni tedavi konseptlerinin de\u011ferlendirilmesi\/standartla\u015ft\u0131r\u0131lmas\u0131 i\u00e7in kay\u0131t<\/li>\n<\/ul>\n<\/div><\/div><\/div><\/section>\n

      G\u00f6zlemsel \u00e7al\u0131\u015fmalar:<\/strong><\/p>\n

        \n
      • Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients (CRISP)<\/i>-\u00e7al\u0131\u015fmas\u0131<\/li>\n
      • Metastatik, skuam\u00f6z olmayan NSCLC ve y\u00fcksek riskli genetik de\u011fi\u015fiklikleri olan hastalarda Tremelimumab + Durvalumab + platin kemoterapisinin (TDC) etkinli\u011fini incelemek \u00fczere prospektif giri\u015fimsel olmayan \u00e7al\u0131\u015fma (NIS)<\/li>\n<\/ul>\n

        Uygulama g\u00f6zlem \u00e7al\u0131\u015fmalar\u0131:<\/strong><\/p>\n

          \n
        • TTFields Plevral mezotelyomal\u0131 hastalarda genel rutin klinik bak\u0131mda \u00e7al\u0131\u015fmas\u0131 (TIGER <\/i>Meso<\/i>)-<\/i>\u00e7al\u0131\u015fmas\u0131<\/li>\n<\/ul>\n

          M\u00fcdahale \u00e7al\u0131\u015fmalar\u0131<\/strong><\/p>\n

            \n
          • Skuam\u00f6z olmayan (NSQ), Evre IV veya n\u00fcks k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri olan ve t\u00fcm\u00f6r h\u00fccresi PD-L1 ekspresyonu \u2265 1% olan kat\u0131l\u0131mc\u0131larda birinci basamak tedavi olarak kemoterapi ile Nivolumab + Relatlimab sabit doz kombinasyonunun, kemoterapi ile Pembrolizumab\u2019a kar\u015f\u0131 de\u011ferlendirildi\u011fi Faz 3, randomize, a\u00e7\u0131k etiketli \u00e7al\u0131\u015fma<\/li>\n
          • Daha \u00f6nce tedavi edilmemi\u015f, lokal ileri veya metastatik skuam\u00f6z olmayan k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri ve KRAS G12C mutasyonu olan kat\u0131l\u0131mc\u0131larda Adagrasib + Pembrolizumab + kemoterapinin, plasebo + Pembrolizumab + kemoterapiye kar\u015f\u0131 de\u011ferlendirildi\u011fi randomize, \u00e7ift k\u00f6r, Faz 3 \u00e7al\u0131\u015fma (KRYSTAL-4)<\/li>\n
          • T\u00fcm\u00f6rlerinde y\u00fcksek PD-L1 ekspresyonu g\u00f6steren metastatik k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri hastalar\u0131nda birinci basamak tedavi i\u00e7in Ivonescimab\u2019\u0131n Pembrolizumab\u2019a kar\u015f\u0131 de\u011ferlendirildi\u011fi randomize, \u00e7ift k\u00f6r, \u00e7ok b\u00f6lgeli Faz 3 \u00e7al\u0131\u015fma (HARMONi-7)<\/li>\n
          • Rezeke edilmi\u015f veya rezeke edilemeyen KRAS G12C mutasyonlu k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri olan kat\u0131l\u0131mc\u0131larda standart bak\u0131m imm\u00fcnoterapisi ile kombinasyon halinde Olomorasib\u2019in etkinlik ve g\u00fcvenlili\u011fini de\u011ferlendiren Faz 3, \u00e7ok merkezli, \u00e7ift k\u00f6r, plasebo kontroll\u00fc \u00e7al\u0131\u015fma – SUNRAY-02<\/li>\n<\/ul>\n<\/div><\/div><\/div><\/section>\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":102,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-4096","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/pages\/4096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/comments?post=4096"}],"version-history":[{"count":3,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/pages\/4096\/revisions"}],"predecessor-version":[{"id":4099,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/pages\/4096\/revisions\/4099"}],"wp:attachment":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/media?parent=4096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}